)
West Pharmaceutical Services (WST) investor relations material
West Pharmaceutical Services Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Customer engagement and strategy
Prioritizing relationships with pharma and biotech supply-chain leaders to understand demand scenarios, clinical pipelines and manufacturing needs beyond procurement-level order discussions.
Planning regular, customer-specific engagement, including reciprocal site visits and agendas on innovation adoption and contamination control.
Customer discussions are in early stages; insights on delivery technologies and modalities may guide relevant product extensions over time.
Organic growth, product upgrades and productivity remain priorities; inorganic options may be evaluated patiently as customer needs become clearer.
Demand and customer visibility
GLP-1s represent ~10% of total revenue; broad market participation, access gains and next-generation products support optimism on the class’s long-term growth.
Growth is broad-based, with HVP upgrades also contributing; management described GLP-1s as a continuing growth tailwind.
Customers typically provide a view of the coming year during annual planning; order patterns become firmer as delivery approaches.
Diverse customers and products, alongside lasting demand trends, support management’s confidence in aggregate growth prospects for the period ahead.
HVP upgrades and capacity
HVP upgrades are expected to add 200 bps of growth in 2026; more than 800 projects are completed or underway, with additional projects in the pipeline.
Europe has upgraded a little over 1 billion of an estimated 6 billion components, or about 20%; projects are expanding in the U.S., where adoption remains early.
Management views the upgrade cycle as a durable, multi-year tailwind, supported by contamination-control requirements and regulatory expectations across regions.
Upgrades can raise price and margin percentage at similar volumes; NovaPure products are positioned to support further movement to higher standards.
Molding capacity is expected to be sufficient through at least decade-end; added finishing capacity is planned to come online in late 2028 as volumes grow.
- HVP-led growth lifted Q3 results and drove higher FY 2026 guidance.WST
Q3 2026 - Strong Q2 growth, premiumization, and regulatory tailwinds drive robust outlook.WST
Morgan Stanley 24th Annual Global Healthcare Conference - Raised guidance and margin expansion reflect strong HVP-driven growth and strategic investments.WST
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 delivered double-digit sales and EPS growth, prompting raised full-year guidance.WST
Q2 2026 - High-value product growth and market leadership drive strong financial outlook for 2026.WST
46th Annual William Blair Growth Stock Conference - Strong Q1 growth and effective cyber incident response support a positive long-term outlook.WST
Bank of America Global Healthcare Conference 2026 - International growth, pipeline expansion, and diversification drive robust long-term outlook.WST
Bank of America Global Healthcare Conference 2024 - 2025 sales and EPS guidance raised after strong Q1 results, despite restructuring and tariff impacts.WST
Q1 2025 - Biologics and regulatory shifts drive robust growth and margin expansion in high-value packaging.WST
CJS Securities 25th Annual “New Ideas for the New Year” Investor Conference
)
)
)
)
)
)
)
)